Not-resumed groups to rule out confounding effects of chemotherapies apart from resumed TKI in multivariate evaluation. Pemetrexed and docetaxel were utilized considerably much more often within the TKI-resumed group than inside the not-resumed group. Moreover, the proportion of patients who have been treated beyond fourth-line chemotherapy was drastically greater in the TKI-resumed group. The chemotherapies utilised throughout disease progression are summarized in Table four up to fifth-line treatments, which mostlyhttp://dx.doi.org/10.3346/jkms.2013.28.11.1,328 stage IIIB, IV NSCLC patients who had started gefitinib involving 2001 2008 790 sufferers using 3rd line gefitinib 538 patients applied 1st or 2nd line gefitinib 80 patients with ECOG PS 3 or four at beginning 1st line treatment 458 individuals with ECOG PS 2 at starting 1st line therapy 289 individuals with response to gefitinib of PD or SD (PFS six months) 169 individuals with response to gefitinib of CR, PR, or SD (PFS six months) 88 individuals with progression in CNS only or without the need of PD confirmation 81 sufferers with confirmed PD except progression in CNS only Fig. 1. Algorithm for the identification of patients with sophisticated non-small cell lung cancer and clinically acquired resistance to gefitinib. NSCLC, non-small cell lung cancer; ECOG PS, ECOG performance status; PFS, progression-free survival; CR, total response; PR, partial response; SD, stable illness; CNS, central nervous system.http://jkms.orgKim H, et al. ?Survival soon after Progression on GefitinibTable 1. Patient characteristics Characteristics Total sufferers Resumed TKI Gefitinib Erlotinib Age 65 yr Female Under no circumstances smoker Adenocarcinoma ECOG PS 0-1 at the start of gefitinib Initial stage IV* Variety of metastasis organs 3 PFS for the 1st gefitinib ten months Total No. ( ) 81 TKI resumed No. ( ) 16 11 (68.7) five (31.3) 3 (18.8) 13 (81.three) 13 (81.three) 16 (100.0) 14 (87.five) 14 (87.5) 7 (43.eight) 9 (56.3) TKI not resumed No. ( ) 65 22 (33.8) 50 (76.9) 46 (70.8) 61 (93.eight) 45 (69.2) 60 (92.3) 24 (36.9) 34 (52.three) P25 (30.9) 63 (77.eight) 59 (72.eight) 77 (95.1) 59 (72.8) 74 (91.4) 31 (38.3) 43 (53.1)0.367 1.000 0.537 0.580 0.212 0.620 0.615 0.Tested by Fisher’s precise test and chi-square test; *staging in accordance with the revised International Technique for Staging Lung Cancer. TKI, tyrosine kinase inhibitor (gefitinib and erlotinib); ECOG, Eastern Cooperative Oncology Group; PS, functionality status; PFS, progression-free survival.Table two. Progression-free survival analysis Variables Age Gender Smoking Histology ECOG PS Initial stage PBC Gefitinib timing Category 65 (n = 56) 65 (n = 25) Female (n = 63) Male (n = 18) Never (n = 59) Ever (n = 22) ADC (n = 77) non-ADC (n = 4) 0-1 (n = 59) two (n = 22) IIIB (n = 7) IV (n = 74) Just before gefitinib (n = 25) Not prior to (n = 56) 1st line (n = -33) 2nd line (n = 48) Univariate evaluation Median PFS months (95 CI) 9.Buy921619-89-8 eight (7.1-Ethynyl-3,5-dimethylbenzene web 9-11.PMID:35227773 6) 9.five (four.5-14.five) 10.six (three.3-12.3) 7.8 (7.6-13.five) 9.8 (six.9-12.7) 9.eight (six.7-12.9) 9.8 (eight.1-11.five) 8.8 (2.0-15.7) 10.six (7.7-13.five) eight.six (5.9-11.2) 14.9 (14.1-15.7) 9.5 (eight.2-10.9) 9.eight (six.3-13.3) 9.eight (7.7-11.9) 9.9 (6.7-13.two) 9.8 (7.8-11.8) HR (95 CI) 0.78 (0.48-1.26) 1.00 0.71 (0.42-1.20) 1.00 0.68 (0.41-1.12) 1.00 0.96 (0.35-2.64) 1.00 0.93 (0.55-1.55) 1.00 0.39 (0.17-0.90) 1.00 0.64 (0.39-1.06) 1.00 0.81 (0.51-1.28) 1.00 P 0.304 0.197 0.132 0.940 0.766 0.028* 0.082 0.360 0.29 (0.12-0.73) 1.00 0.66 (0.39-1.11) 1.00 0.009* 0.114 0.64 (0.27-1.50) 1.00 0.82 (0.38-1.75) 1.00 0.301 0.605 Multivariate analysis HR (95 CI) PTested by Cox pr.